Objective: To evaluate the value of GeneSearch(TM) BLN assay as an intraoperative diagnostic method of sentinel lymph node metastases in breast cancer patients.
Methods: Ninety consecutive patients were involved in this study. SLNs were intraoperatively identified and dissected, and then sectioned vertically to the long axis into multiple blocks. The odd blocks were tested by BLN assay and even ones prepared for frozen sectioning (FS), while all blocks were evaluated by touch imprint cytology (TIC). Post-operatively, residual tissues of the even blocks were assessed by histopathologic examination (4 - 6 µm thick serial sectioning permanent H&E slides were performed every 150 µm and one block made 6 slides).
Results: BLN assay could be performed within less than 35 min after learning curve of 10 cases. A correlation was found between cycle time values of mammaglobin or cytokeratin-19 and size of metastases, with Spearman correlation coefficients of 0.67 and 0.71, respectively. The accuracy, sensitivity, specificity, positive predict value (PPV) and negative predict value (NPV) of the assay were 95.6%, 93.3%, 96.7%, 93.3% and 96.7%, While FS had the sensitivity, specificity, PPV, NPV of 76.7%, 100%, 100%, 89.6%, and TIC of 73.3%, 100%, 100%, 88.2%, respectively. The sensitivity of the assay was higher than that of FS (P = 0.07), and was significantly higher than that of FS (P = 0.04). When assessing patients with micro-metastases, the assay had a sensitivity of 85.7%, which was significantly higher than that of FS and TIC (P = 0.03).
Conclusion: GeneSearch(TM) BLN Assay can replace FS and TIC for the intraoperative assessment of SLN.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants.
Commun Med (Lond)
January 2025
URC EST, Sorbonne Université, Paris, France.
Background: We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech).
View Article and Find Full Text PDFPredicting the replicability of social and behavioural science claims in COVID-19 preprints.
Nat Hum Behav
December 2024
Department of Psychology, University of Cambridge, Cambridge, UK.
Replications are important for assessing the reliability of published findings. However, they are costly, and it is infeasible to replicate everything. Accurate, fast, lower-cost alternatives such as eliciting predictions could accelerate assessment for rapid policy implementation in a crisis and help guide a more efficient allocation of scarce replication resources.
View Article and Find Full Text PDFThe potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial.
Lancet Planet Health
December 2024
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Background: The health-care sector is responsible for 5·2% of global emissions, however, little data exist regarding the environmental impact of disease management strategies. SGLT2 inhibitors are now widely used to reduce the risk of hospital admission and kidney failure in people with type 2 diabetes and chronic kidney disease. This study aimed to estimate the impact of SGLT2 inhibitors on greenhouse gas emissions using data from the CREDENCE trial.
View Article and Find Full Text PDFA self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates.
Nat Commun
November 2024
Janssen Vaccines and Prevention B.V., Leiden, The Netherlands.
Newly approved subunit and mRNA vaccines for respiratory syncytial virus (RSV) demonstrate effectiveness in preventing severe disease, with protection exceeding 80% primarily through the generation of antibodies. An alternative vaccine platform called self-amplifying RNA (saRNA) holds promise in eliciting humoral and cellular immune responses. We evaluate the immunogenicity of a lipid nanoparticle (LNP)-formulated saRNA vaccine called SMARRT.
View Article and Find Full Text PDFA seroprevalence study indicates a high proportion of clinically undiagnosed MPXV infections in men who have sex with men in Berlin, Germany.
BMC Infect Dis
October 2024
Centre for Biological Threats and Special Pathogens, Biological Toxins (ZBS 3), Robert Koch Institute, Berlin, Germany.
Article Synopsis
- The 2022 mpox outbreak in Berlin primarily affected men who have sex with men (MSM), highlighting a need to understand the prevalence of undiagnosed cases.
- A cross-sectional study was conducted, involving 1,119 MSM participants who provided socio-demographic data and blood samples for serological analysis to identify mpox infections.
- The study found that 7.4% reported a previous mpox diagnosis and identified an additional 91 cases of suspected undiagnosed infections, with those affected more likely to have had multiple condomless anal sex partners.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!